Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 2/20 | 0.54 |
| ▸ | MC4R | P32245 | 2/20 | 0.52 |
| ▸ | ACE | P12821 | 2/20 | 0.52 |
| ▸ | PRKACB | P22694 | 1/20 | 0.51 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31593250 | 0.96 | GHSR (0.58) | GHSRMC4RPRKACB | |
| SCHEMBL29485117 | 0.94 | PRKACB (0.55) | GHSRMC4RACEPRKACBKISS1R | |
| SCHEMBL31593302 | 0.93 | NPBWR1 (0.54) | GHSRMC4RPRKACBKISS1R | |
| SCHEMBL30492107 | 0.92 | PRKACB (0.57) | GHSRMC4RPRKACBKISS1REPHX2 | |
| SCHEMBL31593284 | 0.92 | NPBWR1 (0.58) | GHSRPRKACB | |
| SCHEMBL30641906 | 0.91 | PRMT1 (0.52) | MC4RACEPRKACB | |
| SCHEMBL30264785 | 0.91 | GHSR (0.55) | GHSRMC4RKISS1R | |
| SCHEMBL31593260 | 0.91 | NPBWR1 (0.57) | GHSRPRKACB | |
| SCHEMBL13604887 | 0.90 | MC4R (0.57) | MC4RACEKISS1R | |
| SCHEMBL30200105 | 0.90 | ACE (0.52) | GHSRACEKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372525-A1 | TRANSGLUTAMINASE CONJUGATION METHOD WITH AMINO ACID-BASED LINKERS | ARARIS BIOTECH AG (CH) | 2023-11-23 | — | — | US | disclosed |
| EP-4213886-A1 | TRANSGLUTAMINASE CONJUGATION METHOD WITH AMINO ACID-BASED LINKERS | Araris Biotech AG (CH) | 2023-07-26 | — | — | EP | disclosed |
| CN-116406302-A | Method of transglutaminase conjugation with amino acid based linkers | 阿拉里斯生物技术股份公司 | 2023-07-07 | — | — | CN | disclosed |
| WO-2022058594-A1 | TRANSGLUTAMINASE CONJUGATION METHOD WITH AMINO ACID-BASED LINKERS | ARARIS BIOTECH AG (CH) | 2022-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372525-A1 | TRANSGLUTAMINASE CONJUGATION METHOD WITH AMINO ACID-BASED LINKERS | SP1, GLUL, TGM2 | GHSR 1753/4885MC4R 3961/4885ACE 2865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.